To the best of our knowledge, this is the first study to provide information about feasibility and tolerability of the combination cisplatin/gemcitabine in the adjuvant treatment of NSCLC.

Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary ...